Studies combining imatinib with chemotherapy for de novo Philadelphia chromosome–positive (Ph+) ALL.
| Reference . | N (evaluated) . | Age. y (range) . | Imatinib, mg/d . | ChThx regimen . | Schedule of TKI and ChThx . | CR,% . | PCR negative,% . | Induction death, n (&) . | Relapse,% . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|---|
| DFS indicates disease-free survival; EFS, event free survival; OS, overall survival; CR, complete remission; ChThx, chemotherapy; TKI, tyrosine kinase inhibitor; IND, induction; c, consolidation; M, alternating; VCR, vincristine; DEX, dexamethasone; hyper-CVAD, fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; C, concurrent; A, alternating; NR, not reported; na, not applicable; GIMEMA, Gruppo Italiano Malattie EMatologiche dell’Adulto; GMALL, German Multi-Centre Acute Lymphoblastic Leukemia; GRAALL, Group for Research in Adult Acute Lymphoblastic Leukemia; JALSG, Japan Adult Leukemia Study Group; GRAAPH, Group for Research on Adult Acute Lymphoblastic Leukemia. | ||||||||||
| *39 patients with de novo Ph+ALL, 6 pts. refractory to one prior treatment cycle | ||||||||||
| Lee KH 2005 6 | 20 | 37 (15–67) | 600 (IND) 400 (C+M) | Modified from Linker | Concurrent | 95 | NR | 1 (5) | 32 | OS (2y): 59% EFS (2y): 62% |
| Yanada M 2006 7 | 80 | 48 (15–63) | 600 | JALSG ALL202 | Concurrent/sequential | 96 | 71 | 2 (2.5) | 25 | OS (1y): 76% EFS (1y): 60% |
| Wassmann B 2006 8 | 92 (47+45) | 46 (21–65) 41 (19–63) | 400/600 | GMALL 06/99 and 07/03 alloSCT (77%) | Sequential/concurrent | 95 | 19 vs 52 | 0 | NA | OS (2y): 36% (sequential) 43% (concurrent) DFS (2y): 52% (sequential) 61% (concurrent) |
| De Labarthe A 2007 9 | 45 | 45 (16–59) | 600 | GRAAPH-2003 | Concurrent | 96 | 38 | 2 (4) | 19 | OS (1.5y): 65% DFS (1.5y): 51% |
| Thomas, DA 2008 10 | 45* | 51 (17–84) | 600 | HyperCVAD alloSCT (33%) | D1–14 of each cycle | 93 | 52 | 1 (2) | 22 | OS (3y): 66% with SCT 49% without SCT |
| Chalandon, 2008 11 | 83 (42+41) | 42 | 800 | VCR+DEX vs HyperCVAD; alloSCT (n = 41) | D1–28 D1–14 | 100 vs 95 | 48 vs 72 | 1 (1.2) | 22 | OS (2y): 62% DFS (2y): 43% |
| Delannoy A 2006 17 | 30 | – | 600 | GRAALL AFR09 | Concurrent Alternating | 72 | – | – | 60 | OS (1y): 58% DFS (1y): 66% |
| Rea D 2006 15 | 31 | – | 600 | GRAALL AFR07 (pilot) | Concurrent | 90 | – | – | NR | OS (1y): 60% DFS (1y): 48% |
| Ottmann OG 2007 16 | 55 (28+27) | 600 | IM (induction) GMALL-elderly | Concurrent | 96 50 | – | – | 41 54 | ||
| Reference . | N (evaluated) . | Age. y (range) . | Imatinib, mg/d . | ChThx regimen . | Schedule of TKI and ChThx . | CR,% . | PCR negative,% . | Induction death, n (&) . | Relapse,% . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|---|
| DFS indicates disease-free survival; EFS, event free survival; OS, overall survival; CR, complete remission; ChThx, chemotherapy; TKI, tyrosine kinase inhibitor; IND, induction; c, consolidation; M, alternating; VCR, vincristine; DEX, dexamethasone; hyper-CVAD, fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; C, concurrent; A, alternating; NR, not reported; na, not applicable; GIMEMA, Gruppo Italiano Malattie EMatologiche dell’Adulto; GMALL, German Multi-Centre Acute Lymphoblastic Leukemia; GRAALL, Group for Research in Adult Acute Lymphoblastic Leukemia; JALSG, Japan Adult Leukemia Study Group; GRAAPH, Group for Research on Adult Acute Lymphoblastic Leukemia. | ||||||||||
| *39 patients with de novo Ph+ALL, 6 pts. refractory to one prior treatment cycle | ||||||||||
| Lee KH 2005 6 | 20 | 37 (15–67) | 600 (IND) 400 (C+M) | Modified from Linker | Concurrent | 95 | NR | 1 (5) | 32 | OS (2y): 59% EFS (2y): 62% |
| Yanada M 2006 7 | 80 | 48 (15–63) | 600 | JALSG ALL202 | Concurrent/sequential | 96 | 71 | 2 (2.5) | 25 | OS (1y): 76% EFS (1y): 60% |
| Wassmann B 2006 8 | 92 (47+45) | 46 (21–65) 41 (19–63) | 400/600 | GMALL 06/99 and 07/03 alloSCT (77%) | Sequential/concurrent | 95 | 19 vs 52 | 0 | NA | OS (2y): 36% (sequential) 43% (concurrent) DFS (2y): 52% (sequential) 61% (concurrent) |
| De Labarthe A 2007 9 | 45 | 45 (16–59) | 600 | GRAAPH-2003 | Concurrent | 96 | 38 | 2 (4) | 19 | OS (1.5y): 65% DFS (1.5y): 51% |
| Thomas, DA 2008 10 | 45* | 51 (17–84) | 600 | HyperCVAD alloSCT (33%) | D1–14 of each cycle | 93 | 52 | 1 (2) | 22 | OS (3y): 66% with SCT 49% without SCT |
| Chalandon, 2008 11 | 83 (42+41) | 42 | 800 | VCR+DEX vs HyperCVAD; alloSCT (n = 41) | D1–28 D1–14 | 100 vs 95 | 48 vs 72 | 1 (1.2) | 22 | OS (2y): 62% DFS (2y): 43% |
| Delannoy A 2006 17 | 30 | – | 600 | GRAALL AFR09 | Concurrent Alternating | 72 | – | – | 60 | OS (1y): 58% DFS (1y): 66% |
| Rea D 2006 15 | 31 | – | 600 | GRAALL AFR07 (pilot) | Concurrent | 90 | – | – | NR | OS (1y): 60% DFS (1y): 48% |
| Ottmann OG 2007 16 | 55 (28+27) | 600 | IM (induction) GMALL-elderly | Concurrent | 96 50 | – | – | 41 54 | ||